Kendall Capital Partners

EpiBone is a biotechnology company specializing in regenerative medicine for bone repair. It uses patient-specific stem cells and 3D fabrication to create living, anatomically precise bone grafts. The company's lead product has completed Phase I/IIa clinical trials, with additional products focusing on cartilage repair under development.

Omnipulse Biosciences, based in Cambridge, Massachusetts, is a drug development company operating in stealth mode. It specializes in producing single injection quantities of pharmaceuticals, catering to the needs of clinical trials and facilitating access to low-income countries.

EpiBone is a biotechnology company specializing in regenerative medicine for bone repair. It uses patient-specific stem cells and 3D fabrication to create living, anatomically precise bone grafts. The company's lead product has completed Phase I/IIa clinical trials, with additional products focusing on cartilage repair under development.

Founded in 2010, Eyenuk develops artificial intelligence-based solutions for eye disease detection and tracking. Its flagship product, EyeArt AI Eye Screening System, is extensively validated for autonomous diabetic retinopathy detection. The company aims to screen every eye globally, enabling timely diagnosis of conditions like glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer's disease.

Founded in 2020, Bilayer Therapeutics is a biotechnology company based in Cambridge, Massachusetts. It specializes in developing first-in-class therapies using bile acids to treat various colon-related diseases, including chronic idiopathic constipation and irritable bowel syndrome with constipation.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, that focuses on developing gene therapies to enhance health and extend the lifespans of dogs and other domesticated animals. Founded in 2017, the company utilizes innovative approaches derived from research at the Wyss Institute at Harvard Medical School to create anti-aging therapies and address age-related diseases. By introducing new DNA instructions into the bodies of pets, Rejuvenate Bio aims to offer solutions for chronic conditions and improve overall well-being. The company's gene therapy pipeline is designed to target specific diseases and leverage clinically validated gene targets to ensure effective and lasting results.